製品名:2-bromo-3-(2-chlorobenzoyl)pyridine

IUPAC Name:2-bromo-3-(2-chlorobenzoyl)pyridine

CAS番号:622372-89-8
分子式:C12H7BrClNO
純度:95%+
カタログ番号:CM1075076
分子量:296.55

包装単位 有効在庫 価格(USD) 数量

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:622372-89-8
分子式:C12H7BrClNO
融点:-
SMILESコード:ClC1=CC=CC=C1C(=O)C1=CC=CN=C1Br
密度:
カタログ番号:CM1075076
分子量:296.55
沸点:
MDL番号:
保管方法:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Tradipitant
Vanda announced that the FDA has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. If approved, tradipitant will be the first novel drug to be approved by the FDA for the treatment of gastroparesis in over 40 years and to be accepted for review by the FDA for gastroparesis in over 30 years. Tradipitant is an NK-1R antagonist. It works by blocking substance P, a small signaling molecule. Tradipitant can affect gastric peristalsis and directly affect neurotransmission in the brain area responsible for nausea and vomiting, thus playing a role in the treatment of symptoms of gastroparesis. This NDA is mainly based on the results of the Phase II VP-VLY-686-2301 study and the Phase III VP-VLY-686-3301 study.